01:12 , Jun 16, 2018 |  BioCentury  |  Finance

No easy way up

A prolonged period of underperformance at Allergan plc (NYSE:AGN) has activists agitating for change, but there likely aren’t any quick fixes. Looming competition and IP setbacks for key franchises, a mixed business development record and a...
20:49 , Feb 16, 2018 |  BC Week In Review  |  Company News

Teva, Allergan settle working capital dispute

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA; Tel Aviv:TEVA) said Allergan plc (NYSE:AGN) agreed to pay Teva $700 million to settle a dispute that arose after Teva purchased Allergan's global generic pharmaceuticals business. In November 2017, Teva said...
21:02 , Jan 26, 2018 |  BC Week In Review  |  Company News

BIA intervenes on plausibility in patent law in Supreme Court case

The U.K. Bioindustry Association said the U.K. Supreme Court granted it permission to intervene in the court's review of Warner-Lambert Company LLC v. Generics UK Ltd and Actavis to examine the issue of plausibility in...
21:38 , Jan 5, 2018 |  BC Week In Review  |  Financial News

Oculis raises CHF20M series B

Oculis S.A. (Lausanne, Switzerland) raised CHF20 million ($20.3 million) on Jan. 4 in a tranched series B round led by Bay City Capital, Novartis Venture Fund and Pivotal bioVenture Partners with participation by existing investors...
08:02 , Jan 4, 2018 |  BC Extra  |  Financial News

Oculis raises CHF20M series B

Oculis ehf (Lausanne, Switzerland) raised CHF20 million ($20.3 million) in a series B round led by Bay City Capital, Novartis Venture Fund and Pivotal bioVenture Partners. Existing investors Brunnur Ventures and Silfurberg also participated. The round...
21:20 , Nov 9, 2017 |  BC Innovations  |  Finance

The return of big

After a slow second quarter, pharmas have stepped up their activity in public-private partnerships, announcing 13 in 3Q17, compared with only five in the quarter before. The deals bring the third quarter total to 56,...
00:22 , Aug 4, 2017 |  BC Extra  |  Financial News

Teva slides on 2Q results, guidance and dividend cuts

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA; Tel Aviv:TEVA) plummeted $7.50 (24%) to $23.75 Thursday after reporting lower than expected 2Q17 earnings, cutting its dividend and announcing details of a restructuring plan. Teva reported 2Q17 non-GAAP EPS...
07:16 , Jul 29, 2017 |  BioCentury  |  Finance

Show us your shorts

Absent any data showing a sustained impact of manipulative short selling on biotech valuations or their ability to raise capital, it is difficult to discern what direct benefit biotech companies would gain from BIO’s call...
23:43 , Jun 28, 2017 |  BC Extra  |  Company News

Sarepta names Ingram CEO

Sarepta Therapeutics Inc. (NASDAQ:SRPT) named Douglas Ingram president and CEO. He will succeed Edward Kaye, who had been planning to step down (see BioCentury Extra, April 27). Ingram was president and CEO of Chase Pharmaceuticals Corp.,...
22:15 , Jan 6, 2017 |  BioCentury  |  Finance

Good riddance

  Investors aren’t lamenting the end of 2016, but they are pinned between anxiety and optimism for the year ahead. The anxiety stems from uncertainty about U.S. government policies for healthcare under the new administration. The continued...